HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bowron, A. Search for Related Content PubMed PubMed Citation Articles by Bowron, A.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Practical considerations in the use of apomorphine injectable

From the Jubilee Day Hospital, North Tyneside General Hospital, Tyne and Wear, United Kingdom.

Address correspondence and reprint requests to Annette Bowron, Practice Development Nurse-Parkinson’s Disease, Jubilee Day Hospital, North Tyneside General Hospital, Rake Lane North Shields, Tyne and Wear NE29 8NH, UK.

This manuscript provides a practical summary of guidelines for institution of apomorphine subcutaneous injectable therapy, including patient education, pre-treatment issues, dosage titration and side-effect care. The timing of each injection is crucial if an impending "off" period is to be averted. Patients need to be aware of symptoms of an approaching "off" period, and the injection should be administered at the onset or ideally, in anticipation of an "off" episode. Patients being considered for apomorphine treatment should undergo pre-treatment assessment and optimization of ongoing oral therapy prior to initiation. Education and counseling regarding the benefits of apomorphine can often alleviate this. In addition, and where available, it is beneficial to provide the patient and caregiver(s) with additional written information and videos provided by the manufacturer demonstrating the operation of the pump or pen injection systems. Once a patient has been assessed as being a suitable candidate for apomorphine, an apomorphine challenge is performed to determine responsiveness and guide appropriate dosing, establish an individual dose, and to observe for side effects, such as nausea, postural hypotension, excessive somnolence, or dyskinesia. Three days prior to the challenge, domperidone 20 mg tid or trimethobenzamide (Tigan®) 300 mg tid is recommended. Potential side effects include yawning, dopaminergic side effects, such as dyskinesias, nausea, orthostatic hypotension, confusion, hallucinations, somnolence and rarely, hypersexuality or other behavioral disturbances, and skin nodule formation.

This article has been cited by other articles:

				C. Pot, R. Oppliger, V. Castillo, A. Coeytaux, C. Hauser, and P. R. Burkhard Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease Neurology, January 25, 2005; 64(2): 392 - 393. [Full Text] [PDF]

				D. M. Swope Rapid treatment of "wearing off" in Parkinson's disease Neurology, March 23, 2004; 62(6_suppl_4): S27 - S31. [Abstract] [Full Text]